Treatment Of Dysuria Research Articles

Efficacy of methenamine with methylthioninium in the treatment of dysuria: a randomized clinical study

Introduction and hypothesisDysuria is a common symptom present in several urological and gynecological conditions. Management relies on the underlying disease but may require additional symptomatic treatment. This study evaluated the combination of methenamine 250 mg and methylthioninium chloride 20 mg in the treatment of dysuria versus phenazopyridine.MethodsThis was a multicenter, single-blind, randomized, superiority clinical trial, including individuals over 18 with dysuria and a score ≥ 5 points on the pre-treatment categorical scale for pain. The primary outcome was the proportion of participants presenting excellent clinical response within 24 h after treatment. Improvement up to 72 h, time to reach improvement, sustained healing, investigators’ opinion, and safety were also evaluated.ResultsThree hundred and fifteen participants were evaluated. Demographic characteristics and symptoms of dysuria were comparable between groups at baseline. The difference in the excellent response rate between treatments within 24 h was 12.7% (95% CI 6.16, 19.21) for pain, 9.4% (95% CI 3.32, 15.39) for burning, and 12.7% (95% CI 6.37, 18.99) for burning on urination, all in favor of the test drug, which was also superior from 36 to 48 h. Treatments were similar concerning time to reach the absence of symptoms and in the percentage of participants with sustained healing after 72 h.ConclusionsThe association of methenamine with methylthioninium is superior to phenazopyridine in the treatment of dysuria.

Identifikasi Senyawa Metabolit Sekunder Ekstrak Daun Bintaro (Cerbera manghas L.) Dengan Pelarut Etanol 70%, Aseton dan n-Hexan

Bintaro (Cerbera manghas L.) is widely used as an analgesic, anticonvulsant, cardiotonic, and hypotensive activity. In Thailand bintaro is used as traditional medicine such as bark used as an antipyretic, laxative and in the treatment of dysuria. The flower part is applied to treat hemorrhoids. Secondary metabolites are chemical compounds contained in plants that can be drawn by a suitable solvent through extraction methods. The purpose of this study was to determine the content of secondary metabolites contained in bintaro leaf extract using ethanol, acetone, and n-Hexan solvents based on phytochemical screening. This research was carried out through two stages, namely extraction using maceration method using ethanol, acetone, n-Hexan and phytochemical screening solvents consisting of screening alkaloids, terpenoids, flavonoids, steroids, saponins, and tannins. The results showed that the bintaro leaf ethanol extract positively contained flavonoids, saponins, and tannins. The acetone extract of bintaro leaves positively contains, saponins and tannins. N-hexan daun bintaro extract positively contained steroids and alkaloids in testing with Dragendorft reagents, and was positive for Wagner reagents and negative for testing with Mayer reagents

Effectiveness of pharmaceutical support by pharmacists in urinary care teams

To facilitate timely removal of urinary catheters and promote self-voiding among inpatients, urinary care teams have been established in some Japanese medical institutions. However, direct evidence of the effectiveness of pharmacist intervention in urinary care teams is limited. We evaluated the efficacy of pharmaceutical support by a pharmacist in a urinary care team. Between September 2017 and August 2018, 84 patients met the criteria for initiating continuous intervention. Patients with (20 cases) and without (8 cases) adoption of pharmaceutical support (initiation or discontinuation of treatment for dysuria) were scored for urinary function (including degree of independence of urination and score of lower urinary tract disorder) and for urinary situation. Comparative analysis results showed that pharmacist intervention in the adoption cases resulted in significantly improved scores for urinary function than in non-adoption cases. Similarly, pharmaceutical support resulted in improved overall urinary situation in the patients (85.0% of adoption cases compared to 37.5% of the non-adoption cases). The most common pharmaceutical support was a recommendation to discontinue drugs that induce dysuria (65.0% of the cases). Taken together, our findings suggested that pharmacists are important members of urinary care teams.

Evaluation of an early twentieth century Afghan herbalist’s preparations

Mahomet Allum was a flamboyant philanthropist and herbalist who worked in South Australia in the early part of last century, whose herbal therapies generated some controversy at the time. Two of his preparations have survived to the present day, a general tonic and a treatment for liver and kidney dysfunction. Given the frequent use of pharmaceutical drugs in "tonics" at the time, toxicological analysis was undertaken at Forensic Science SA, Adelaide with liquid chromatography/quadrupole-time-of-flight mass-spectrometer (LC-QTOF MS), liquid-chromatography/ diode array detector (LC/UV) and gas chromatography/ nitrogen phosphorous- detector/mass-spectrometer (GC-NPD/MS), to look for common drugs. In addition DNA analysis was also undertaken at Trace and Environmental DNA (TrEnD) Laboratory (Curtin University) to evaluate the types of plant products used to make these remedies. The general tonic contained genera from the Triticeae (wheat) family as well as the Medicago family (includes alfalfa), possibly as fillers. Other genera found included Utrica (nettle) and Passiflora (passion flower). The preparation for liver and kidney disease also contained genera from the Medicago family as well as genera Arctostaphylos (bear berry) which has traditionally been used for the treatment of dysuria and bladder stones. No common drugs were found. Thus it appears that the two treatments prepared by Mahomet Allum contained only herbal substances and not adulterant pharmaceutical agents. The herbals identified provide an insight into herbalist practices in the early twentieth century.

Ethnopharmacological Study of Medicinal Plants Used for Treating Dysuria: A Collection from Traditional Markets in Shiraz

Background: Data from the ethnopharmacological field on the treatment of dysuria are provided and analyzed with regard to traditional healers from Shiraz and in comparison to previous studies. Material and Methods: From April 21 to June 25, 2014, we visited traditional markets called Attari in Shiraz, and plants used in dysuria were collected. Questionnaires asking for general information on the traditional healers named Attars, local names of plant species, plant parts, preparation methods, etc. were prepared in order to gather data from Attars. Results: We visited 40 Attari, and 29 questionnaires were filled in by male Attars. Evaluation of our investigation revealed that Tribulus terrestris, Zea mays, and Cerasus avium were the most common plants suggested by Attars (24, 23, and 23, respectively). Infusion (37%) and decoction (34%) were the most common preparation methods for these plants. 50% of the main effects intended by the Attars were antimicrobial effects, while diuretic effects were reported at 35.7%. The temperament of the plants, as one aspect of the questionnaires, showed that more plants have a hot and dry temperament (47.9%). According to available studies about the plants, we found that flavonoids (78.3%), higher terpenoids (43.5%), and essential oils (39.1%) exist in higher amounts than other components in the plants. Conclusions: We analyzed the information gathered from the questionnaires and from previous studies and found that flavonoids are the most important constituents among the plants, especially those that exist in T. terrestris, Z. mays, and C. avium. Due to the useful effects of flavonoids in urological diseases, we suggest to evaluate and concentrate on the effects of flavonoids in dysuria treatments.

Diuretic and serum electrolyte regulation potential of aqueous methanolic extract of Solanum surattense fruit validates its folkloric use in dysuria.

BackgroundSolanum surattense Burm. (Solanaceae) is traditionally used for management of various ailments. The study was conducted for provision of pharmacological justification for folkloric uses of Solanum surattense in the treatment of dysuria.MethodsRats were randomly divided into 5 groups, each of (n = 6). Aqueous methanolic fruit extract of S. surattense were also administered intraperitoneally to the rats at doses of 50, 70 and 100 mg/kg. Furosemide (10 mg/kg i.p) was used as standard drug whereas controls were given saline solution (40 mL/kg i.p). The electrolytes in urine were measured using a flame photometer whereas serum sodium, potassium, calcium, bicarbonate and blood urea nitrogen (BUN) were determined by using an automatic analyzer. Urine osmolality was assayed by the micro-osmometer.ResultsThe extract S. surattense induced diuretic effects in a dose-dependent manner as compared with control. Upon administration of extract (70 and 100 mg/kg), we observed the prominent (p < 0.01) increase in the urine volume and osmolality in comparison to control group. However, plant extract (100 mg/kg) significantly increase the urinary electrolyte excretion especially calcium (p < 0.05) to that of the furosemide whereas level of magnesium remains constant. Moreover, our results showed a decrease in serum levels of sodium, potassium, calcium and blood urea nitrogen (BUN), but concentration dependent increase in bicarbonate was found in the test groups. There was no substantial change in the pH of urine samples of the extract-treated groups.ConclusionThese results indicate that S. surattense investigated exert its action by causing diuresis in the treatment of dysuria.

EYE ON CHINA

ScinoPharm Taiwan and Coland Holdings establish strategic alliance for oncological injectable products for China. Researchers investigate the effects of thinning on soil respiration and its sensitivity in a pine plantation, eastern Tibetan Plateau. Ascletis gains China market rights from Janssen to a clinical stage HIV protease inhibitor. The genome sequences of soft-shell turtle and green sea turtle offer new clues to the development and evolution of turtle-specific body plan. Daiichi Sankyo launches Silodosin for the treatment of Dysuria in China. China plans research centres to aid developing world. HKU finds novel coronavirus can infect humans respiratory tract even better than SARS-CoV. BGI Health collaborates with Eastern Biotech &amp; Life Sciences on non-invasive fetal Trisomy test for improving reproductive health in the Middle East. Baxter China partners with government to increase access to renal therapy.

Pharmacognostic studies of the leaf and stolon of Pistia stratiotes Linn.

Pistia stratiotes Linn. is found in ponds and streams throughout India. The plant has demulcent, refrigerant activities and useful in the treatment of dysuria. It is considered as antiseptic, antitubercular and antidysenteric. It is used in the preparation of inorganic Ayurveda and Siddha medicaments. The leaves are used in eczema, leprosy, ulcer, piles, and syphilis. The present study deals with the various pharmacognostical examinations include the morphological, microscopical characters and physiochemical characters like ash values and extractive values. The preliminary phytochemical screening is also carried out and it is revealed the presence of various phytoconstituents like Steroid, Triterpenoid, Phenol, Flavanoid, Tanin, Alkaloid, Glycoside and Saponin. These data's could be used to standardize the plant which is essential and is need of the hour.

Cardiovascular Effects of the Selective α1A-Adrenoceptor Antagonist Silodosin (KMD-3213), a Drug for the Treatment of Voiding Dysfunction

The aim of this study was to assess the cardiovascular effects of silodosin (CAS 160970-54-7, (-)-1-(3-hydroxypropyl)-5-[(2R)-2-({2-[2-(2,2,2-trifluoroethoxy) phenoxy]ethyllamino)propyll-2,3-dihy-dro-1H-indole-7-carboxamide, KMD-3213), a potent selective alpha1A-adrenoceptor (AR) antagonist used for the treatment of dysuria. In conscious dogs, orally administered silodosin, at doses (0.2, 2 and 20 mg/kg) considerably higher than the pharmacologically effective dose, decreased blood pressure. These doses, however, had no effects on heart rate or on the electrocardiogram (PR interval, QRS interval, QT interval or QTc). In addition, the cardiac effects of silodosin were evaluated in an in vitro electrophysiological study. Silodosin inhibited the human ether-a-go-go-related gene (HERG) tail current, leaving a residual tail current of 45 % control at 10 micromol/L. However, the concentration that inhibited the HERG tail current was considerably higher than its affinity for alphal-ARs. These results suggest that while the alpha1B-AR subtype is mainly involved in the regulation of blood pressure, the alphalA-AR subtype is not. There seems to exist no evidence of a correlation between the function of alphal-AR and ECG changes reflecting inhibition of the HERG current. The cardiovascular profile of silodosin suggests therefore that it is a safe and well-tolerated drug.

UP-03.054 Clinical Efficacy of Tape-Cutting as a Treatment for Complication in TOT

Compared to the previous treatments for stress incontinence, T0T is used more with its safety and less complication. However it is not free from only the complication, but also the voiding difficulty, on the contrary to the symptoms of complication. Accordingly the purpose of this study is to identify the clinical efficacy of tape cutting as a treatment for dysuria.

Inhibitory effects of selected Thai medicinal plants on Na +,K +-ATPase

Extracts of ten Thai indigenous medicinal plants having ethnomedical application in the treatment of dysuria were tested for their Na +,K +-ATPase inhibitory activity. The hexane extracts of Cyperus rotundus and Orthosiphon aristatus showed high potent inhibitory activity on crude enzyme Na +,K +-ATPase from rat brain.

KMD 3213: KAD 3213, silodosin.

KMD 3213 [silodosin, KAD 3213] is an orally active alpha(1)-adrenoceptor antagonist under development with Kissei (Japan) for the treatment of dysuria associated with benign prostatic hyperplasia (BPH). Daiichi Pharmaceutical and Kissei are conducting phase III trials in Japan, while Kissei's US subsidiary, Kissei Pharma USA Inc., has completed early phase II trials with favourable results for the treatment of dysuria associated with benign prostatic hyperplasia (BPH). Kissei expects to file an NDA application in Japan in July 2004. Daiichi is also preparing a phase I trial in China with this compound for the treatment of dysuria associated with benign prostatic hyperplasia. According to Kissei's 2003 Annual Report, they are currently preparing to license out the development and marketing rights for KMD 3213 in Europe and North America. In March 2002, Daiichi predicted that KMD 3213 has the potential to reach peak sales of approximately 10 billion Japanese yen.

Voiding Function and Dysfunction, Bladder Physiology and Pharmacology, and Female Urology

No AccessJournal of UrologyUROLOGICAL SURVEY: Abstracts1 Jun 2002Voiding Function and Dysfunction, Bladder Physiology and Pharmacology, and Female Urology Alan J. WeinM.D. Alan J. WeinAlan J. Wein More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)65053-7AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail References 1 : The use of estrogens in the treatment of dysuria and incontinence in postmenopausal women. Am J Obstet Gynecol1941; 42: 845. Google Scholar © 2002 by American Urological Association, Inc.FiguresReferencesRelatedDetails Volume 167Issue 6June 2002Page: 2653-2663 Advertisement Copyright & Permissions© 2002 by American Urological Association, Inc.MetricsAuthor Information Alan J. Wein More articles by this author Expand All Advertisement PDF DownloadLoading ...

Diuretic effects of selected Thai indigenous medicinal plants in rats

Extracts of five indigenous Thai medicinal having ethnomedical application in the treatment of dysuria were investigated for their diuretic activity. Root extracts of Ananas comosus and Carica papaya, given orally to rats at a dose of 10 mg/kg, demonstrated significantly increased urine output ( P<0.01) which was 79 and 74%, respectively, of the effect of an equivalent dose of hydrochlorothiazide. Both plant extracts gave similar profiles of urinary electrolyte excretion to that of the hydrochlorothiazide. The analyses of the urinary osmolality and electrolyte excretion per unit time suggest the observed effect of A. comosus was intrinsic, whereas that of C. papaya may have resulted from a high salt content of this extract. However, our experimental evidence on the diuretic activities of the other three plants did not parallel their local utilization for dysuria. It was found that the rhizome of Imperata cylindrica apparently inhibited the urination of rats whereas the rhizome of Cyperus rotundus and the stem of Averrhoa carambola failed to demonstrate any diuretic activities. These results indicate that two of the plants investigated exert their action by causing diuresis. The other three plants need further investigation to determine their effectiveness in the treatment of dysuria.

A Multicenter, Double-Blind, Placebo-Controlled Trial of the Efficacy of Prazosin in the Treatment of Dysuria Associated with Benign Prostatic Hypertrophy

An 8-center, double-blind, placebo-controlled trial of 39 patients with benign prostatic hypertrophy was conducted to assess the effects of prazosin HCl treatment on functional urologic variables after a treatment period of 4 weeks. The randomized groups were comparable for demographic variables and symptoms, except for the mean residual urinary volume, which was significantly higher in the prazosin HCl group. Prazosin HCl elicited statistically significant improvements in the mean prostatic urethral pressure and prostate area (Mann-Whitney U test: p = 0.001 for both variables as compared with the placebo group). Functional bladder capacity also improved significantly in the group receiving the test drug (Mann-Whitney U test: p = 0.05, as compared with the placebo group). Clinical improvements were also observed in the mean maximum urinary flow, decreased nocturia frequency, and residual urinary volume. Patient preference significantly favored the prazosin HCl treatment (Mann-Whitney U test: p = 0.001). Seven patients on prazosin HCl and 5 receiving placebo reported one or more side effects during the trial phase; these were mild to moderate and disappeared or were tolerated. No statistically significant effects on blood pressure or heart rate were observed.

A Strategy for Efficient Diagnosis and Treatment of Dysuria in Women in the Military Setting

A Strategy for Efficient Diagnosis and Treatment of Dysuria in Women in the Military Setting

The use of estrogens in the treatment of dysuria and incontinence in postmenopausal women

The study reported here stems from the observation that a number of women with disorders of micturition, consisting of urinary frequency, urgency, and incontinence, experienced relief of these symptoms while being treated with estrogens for the usual menopausal complaints. In order to determine the relationship of the estrogen therapy to the amelioration of the urinary symptoms, a group of postmenopausal patients with urgency, dysuria, and stress incontinence were selected for study and treatment.